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Abstract
Purpose: The complexity of sarcoma has led to the need for patient selection
via in vivo biomarkers. Tumor endothelial marker-1 (TEM-1) is a cell surface marker
expressed by the tumor microenvironment. Currently MORAb-004 (Ontuxizumab), an
anti-TEM-1 humanized monoclonal antibody, is in sarcoma clinical trials. Development
of positron emission tomography (PET) for in vivo TEM-1 expression may allow
for stratification of patients, potentially enhancing clinical outcomes seen with
Ontuxizumab.
Results: Characterization of cell lines revealed clear differences in TEM-1
expression. One high expressing (RD-ES) and one low expressing (LUPI) cell line
were xenografted, and mice were injected with 89Zr-Ontuxizumab. PET imaging postinjection revealed that TEM-1 was highly expressed and readily detectable in vivo only
in RD-ES. In vivo biodistribution studies confirmed high radiopharmaceutical uptake
in tumor relative to normal organs.
Experimental Design: Sarcoma cell lines were characterized for TEM-1
expression. Ontuxizumab was labeled with 89Zr and evaluated for immunoreactivity
preservation. 89Zr-Ontuxizumab was injected into mice with high or null expressing
TEM-1 xenografts. In vivo PET imaging experiments were performed.
Conclusion: 89Zr-Ontuxizumab can be used in vivo to determine high versus low
TEM-1 expression. Reliable PET imaging of TEM-1 in sarcoma patients may allow for
identification of patients that will attain the greatest benefit from anti-TEM-1 therapy.

Introduction

Tumor endothelial marker-1 (TEM-1), also referred
to as endosialin or CD248, is a tumor vascular marker that
is a 175k-Da type I transmembrane protein of the C-type
lectin-like receptor family [5, 8-10]. It is most closely
related to the family of transmembrane glycoproteins that
includes thrombomodulin, functions in the angiogenesis
process, and may also be involved in cell adhesion
and migration. Its role in other cellular functions is not
fully defined [6, 11-13]. TEM-1 is primarily expressed
on tumor stroma and tumor vessels in multiple human
cancers, but is not expressed in normal adult tissue or
blood vessels [9, 10, 14-16]. A limited number of tumors
have also been demonstrated to express TEM-1. By
immunohistochemistry (IHC), the expression of TEM-

The utility of biomarkers in the diagnosis, staging,
and determination of clinical response to treatment is
emerging as an invaluable tool in the care of cancer
patients [1-4]. The use of a biomarker to not only image
a malignancy, but to offer guidance as to which therapy
would most benefit a patient is at the core of personalized
therapy. The ability to delineate a patient’s clinical
response to a biologic treatment would allow for patient
stratification into groups that would either benefit from
a treatment, or spare patients the costs and potential
toxicities of ineffective treatments [5-7].
www.impactjournals.com/oncotarget
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of generating higher quality images [21]. Secondly, we
sought to examine the feasibility of imaging TEM-1
expression on non-engineered sarcoma cell lines, in vivo,
to assess the potential clinical utility of this agent.
At present, the ability to determine the clinical
expression of TEM-1 in patients with metastatic disease
relies on IHC of biopsies of single lesions or primary
tumors that may not represent true TEM-1 expression
when compared to the total tumor burden in a patient.
Negative staining for TEM-1 may represent an artifact of
processing or biopsy selection, while positive staining may
only relate to the specific tumor that was biopsied and not
the entire tumor burden. We proposed to develop a PET
clinical screening test to determine which patients would
most likely benefit from anti-TEM-1 therapy using 89ZrOntuxizumab.

1 is restricted to stromal cells and tumor-associated
perivascular cells in ovarian, breast, and lung cancers
[17, 18]. In sarcoma, the expression of endosialin/
CD248/TEM-1 has been examined in cell culture, clinical
specimens and animal models, and endosialin was found to
be expressed frequently and at high levels in perivascular
cells, stromal cells. The malignant cells themselves [17,
19, 20]. A high level of endosialin expression on primary
clinical samples of sarcoma suggests the potential utility
of targeting endosialin/CD248/TEM-1 on sarcomas in vivo
[17, 19, 20].
Previous work using a 124I-labled anti-TEM-1
antibody illustrated the feasibility of using PET imaging
to visualize this target in a cell line engineered to express
high levels of TEM-1 [5]. Using 125I-labled Ontuxizumab
TEM-1 positive tumor bearing mice were found to clear
the antibody at a much slower rate that TEM-1 negative
tumor bearing mice [5]. In addition, biodistribution studies
demonstrated high uptake of iodinated Ontuxizumab in
tumors compared to normal tissues [5]. The aims of the
current study were twofold. First, to develop a 89Zr-PET
imaging agent for imaging of TEM-1 expression as 89Zr
is known to be a residualizing radionuclide (trapped
inside cells after metabolism) and thus has the potential

Results
TEM-1 expression in sarcoma cell lines
To identify potential in vivo xenograft candidates,
a panel of thirteen sarcoma cell lines was screened for

Figure 1: TEM-1 Expression: High and Null Expressing Sarcoma Lines. A. FACS analysis using Ontuxizumab antibody and
FITC-labeled anti-human secondary antibody to determine TEM1 expression. RD-ES (Ewing’s sarcoma) and FUJI (synovial sarcoma)
show high TEM-1 expression. LUPI, a Ewing’s sarcoma line, and SYO-1, a synovial sarcoma line, display null to low expression of TEM1, respectively. B. Semi-quantitative immunofluorescence of TEM-1 expression. Cell lines RD-ES and FUJI display strong Ontuxizumab
binding while LUPI and SYO-1 display null binding. Images were captured using an exposure time of 25 msec through a 60x objective
keeping time constant across all images. C. NATIVE-PAGE Western blot showing high-expressing TEM-1 lines RD-ES and FUJI, with
null-expressing lines LUPI and SYO-1.
www.impactjournals.com/oncotarget
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TEM-1 expression by FACS. Three Ewing’s cell lines
(SK-ES, RD-ES, and LUPI), three osteosarcoma cell lines
(MG-63, MNNG-HOS, U2-OS) two synovial sarcoma
cell lines (SYO-1, FUJI), two uterine sarcoma cell lines
(SK-LMS-1, SK-UT), one fibrosarcoma (HT-1080), one
rhabdomyosarcoma (RD), and one malignant peripheral
nerve sheath tumor (MPNST) (ST-88-14) were assessed.
Indirect FACS using Ontuxizumab and FITC-labeled antihuman secondary antibody revealed that cell lines RDES and FUJI displayed very high expression of TEM-1
when compared to background (Figure 1A). Conversely,
LUPI and SYO-1 were null and low expressers of TEM-1,
respectively (Figure 1A). Binding of Ontuxizumab to these
two paired cell lines was confirmed by semi-quantitative
immunofluorescence; using fixed camera settings, the
FITC-labeled anti-human antibody labeling of bound
Ontuxizumab was noted to be positive in RD-ES and FUJI
when compared to LUPI and SYO-1 (Figure 1B). Finally
we performed NATIVE-PAGE Western blot analysis to
confirm the expression of TEM-1 in RD-ES and FUJI
when compared to LUPI and SYO-1 (Figure 1C); a rat
monoclonal antibody to TEM-1 was used as Ontuxizumab
only recognizes a three dimensional structure of TEM-1
that is lost upon immunoblotting. FACS analysis
(Supplemental Figure 1) and immunofluorescence
(Supplemental Figure 2) of the remaining nine sarcoma
cell lines revealed that both SK-ES, a Ewing’s sarcoma,
and ST-88-14, a MPNST, displayed low to moderate

TEM-1 expression, while the remainder of the panel were
null expressers of TEM-1.

DFO conjugation and 89Zr labeling does not affect
binding or uptake of ontuxizumab
Ontuxizumab underwent chelator conjugation
with 89Zr (Figure 2). To determine if 89Zr labeling of
Ontuxizumab altered binding affinity, we performed
binding and uptake assays. Cells were incubated with
the radiolabeled antibody, lysed, and cell associated
activity detected with a gamma-counter. Protein amount
was measured with a BCA assay and the data expressed
as counts per milligram of protein (CPM/mg protein).
Binding of the radiolabeled antibody was significantly
higher for RD-ES and FUJI when compared with LUPI
and SYO-1 (Figure 3A). Immunoreactivity of the
radiolabeled antibody was determined using 89Zr-Df-BzNCS-Ab binding to immobilized TEM-1 in the presence
of increasing amounts of Df-Bz-NCS-Ab (conjugated) or
Ab (unconjugated). When assessing the binding affinity of
unconjugated compared to conjugated antibody, there was
no significant difference in CPM between conjugated and
unconjugated antibody in vitro. Therefore, conjugation of
the DFO and radiolabeling it with 89Zr did not change the
antibody’s binding properties (Figure 3B).
Another recently reported function of Ontuxizumab

Figure 2: Ontuxizumab conjugation. Ontuxizumab was conjugated to p-isothiocyanatobenzyl-desferrioxamine (DFO-Bz-NCS metal
chelate) via lysine residues. After purification, the antibody conjugate was radiolabeled with 89Zr-oxalate under neutral pH conditions.
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is internalization after binding to endosialin [28]. To
determine if 89Zr altered the ability of Ontuxizumab to
internalize after labeling we performed an in vitro uptake
assay using the TEM-1 expressing cell line RD-ES (Figure
3C). We found that the labeled antibody was internalized
slowly, likely at the rate of receptor turnover, and that
this was not saturable over 24 hours, thus suggesting
that radioimmunotherapy or antibody conjugates using
Ontuxizumab may be useful for drug development [29].

injection. PET/CT imaging was performed on postinjection days 3 and 7 and displayed as maximum intensity
projections (MIP) of PET/CT images (Figure 4A). 89Zrlabeled Ontuxizumab highly and reliably accumulated
in vivo in RD-ES xenografts, while LUPI xenografts
displayed lack of uptake (Figure 4A, middle and right
panels, respectively). Background PET activity was not
observed. Specificity of the 89Zr-labeled Ontuxizumab for
the tumor was confirmed by blocking the radiolabeled
antibody uptake with cold antibody administration
(Figure 4A, left panel). Standard uptake values (SUV)
were obtained from PET/CT images at post-injection day
3 and day 7. Significant differences were noted in SUVs
between blocked and non-blocked day 3 and day 7 RDES xenografts (Figure 4B). The SUV from the day 3 and
day 7 PET/CT image analyses of the RD-ES xenografts
was significantly higher than that of the non-blocked day
3 and day 7 SUVs for the LUPI xenografts (Figure 4B). In
vivo biodistribution studies were performed 7 days post-

In vivo PET imaging and biodistribution
One high expressing (RD-ES) and one null
expressing (LUPI) cell line were xenografted with 1x106
cells into nude athymic mice and observed for xenograft
growth until tumor size reached 100 mm3. The mice
were then anesthetized with isoflurane and treated with
100 μCi (50 μg) 89Zr-labeled Ontuxizumab via tail vein

Figure 3: Binding Study and Uptake. A. 89Zr-Df-Bz-NCS-Ab binding to selected sarcoma cell lines. Radiolabeled antibody was
allowed to bind to selected cell lines for 35 min as described in the Methods section. RD-ES and FUJI cells demonstrated good binding
of 89Zr-Df-Bz-NCS-Ab, while SYO-1 and LUPI showed no appreciable binding. B. Immunoreactivity of 89Zr-Df-Bz-NCS-Ab determined
using 89Zr-Df-Bz-NCS-Ab binding to immobilized TEM-1 in the presence of increasing amounts of Df-Bz-NCS-Ab (conjugated) or Ab
(unconjugated). Df-Bz-NCS-Ab IC50 = 13.1 nM, Ab IC50 = 14.5 nM. Assay performed as described in the Methods section.
www.impactjournals.com/oncotarget
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Table 1.

Discussion

PET/CT imaging; after sacrifice, the organs of interest
were harvested, weighed, and radioactivity measured and
reported as the percent of injected dose/gram of tissue.
This confirmed high radiopharmaceutical uptake in RDES non-blocked xenograft relative to normal organs
(Figure 5 and Supplemental Table 1). The ratio of tumor
to muscle uptake was 21.9 in the RD-ED TEM-1+ cell line
which was reduced to 3.59 upon blocking, comparable to
the TEM-1 low expressing cell line LUPI at 4.3.

Sarcomas are an extremely heterogeneous group of
tumors comprising over 50 subtypes that are associated
with distinctive clinical profiles, response to individual
therapies, and prognosis[30]. The reliable identification of
TEM-1 in sarcoma may aid in the selection of patients for
clinical trials that have the highest potential to benefit from
such a targeted therapeutic strategy [5, 6, 19]. However, at

Figure 4: In vivo PET Imaging / Radiopharmaceutical tumor uptake. A. Maximum intensity projections (MIP) of PET/CT
images at 72 hours post-injection of 100 µCi (50 µg) 89Zr-Df-Bz-NCS-Ab. Signal intensity adjusted to equal scale. All data are presented as
mean +/- standard deviation. B. Standard uptake values (SUV) obtained from PET/CT image analyses performed at three and seven days
post injection. Day 3: RD-ES = 7 for block (b) and non-block (n/b), LUPI = 3. The same n for day 7.
www.impactjournals.com/oncotarget

13086

Oncotarget

this time, the ability to determine the clinically relevant
expression of TEM-1 in patients with metastatic disease
relies on biopsies of single lesions of primary tumors
which may not represent the overall TEM-1 expression
in a patient. The use of immunoPET in the imaging of
malignancies has increased in use recently, benefiting from
advances in PET/CT technology, radionuclide chemistry,
and use of improved chelates for radiometal chemistry[4,
5, 7, 25, 31, 32]
We
have
used
FACS
analysis
and
immunofluorescence to identify high and null TEM-1
expressing sarcoma cell lines, and have identified two high
expressing cell lines. RD-ES, a Ewing’s sarcoma line, and
FUJI, a synovial sarcoma line, showed strong binding of
the humanized TEM-1 antibody, Ontuxizumab, via FACS
analysis and immunofluorescence, with confirmation
via Western blotting. Paired cell lines, LUPI (Ewing’s
sarcoma) and SYO-1 (synovial sarcoma), were identified
as null and low expressers of TEM-1, respectively, as were
the remainder of the 13 sarcoma cell lines screened in this
fashion. Ontuxizumab was successfully conjugated to
DFO and labeled with 89Zr without altering the antibody’s
immunoreactivity. It displayed strong affinity to both
high-expressing cell lines, RD-ES and FUJI in vitro. The
in vivo utility of 89Zr-Ontuxizumab was demonstrated
in RD-ES and LUPI xenografts with RD-ES xenografts
displaying significantly higher SUVs at post-injection
PET imaging at both 3 and 7 days when compared to
LUPI xenografts. Blocking of the radiolabeled antibody

at both 3 and 7 days post-injection with unconjugated
Ontuxizumab demonstrated high specificity of the
radiolabeled antibody for the TEM-1 expressing RD-ES
xenografts. Biodistribution studies performed 7 days postinjection of the 89Zr-Ontuxizumab showed accumulation
of the antibody within the target tumor, while non-target
tissues and organs of interest showed very little uptake of
the antibody.
The sequential process of screening cell lines for
a specific monoclonal antibody with subsequent in vivo
demonstration of 89Zr-labeled monoclonal antibody proves
the utility of this in vivo TEM-1 expression PET test for
human clinical screening applications. The findings in
this paper await formal clinical trial testing in humans to
demonstrate the utility of using radiolabeled Ontuxizumab
as the target of the antibody, endosialin, is also expressed
on blood vessels. In addition, the pharmacokinetics of the
antibody’s clearance may be very different in humans than
mice, but this awaits formal testing in humans. Clinically,
reliable PET imaging of anti-TEM-1 antibody in patients
with sarcoma may allow for stratification of patients into
cohorts that will attain the greatest benefit from antiTEM-1 therapy.

Figure 5: Biodistribution. Post PET (Day 7) biodistribution of 89Zr-Df-Bz-NCS-Ab for mice bearing RD-ES (N = 4) and LUPI (N = 3)
xenografts. Data is presented as % ID/g. Blocked animals (N = 4) were pre-administered with 1 mg of native antibody to confirm specificity
of targeting. All data are presented as mean +/- standard deviation.
www.impactjournals.com/oncotarget
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Materials and Methods

H12.E7.G9) was also provided by Morphotek. Purified
TEM-1 antigen was provided by Morphotek, Inc. and
stored at -20°C. HRP-Goat anti-Rat IgG + IgM was from
Jackson ImmunoResearch (West Grove, PA Cat# 112-035068), and anti-human beta-actin was from Sigma Aldrich
(Cat# A1978). Anti-human IgG-FITC was obtained from
Santa Cruz Biotechnology (Santa Cruz, CA, Cat # sc2456).

Reagents
All experiments involving the use of radioactive
materials at Washington University are conducted under
the authorization of the Radiation Safety Committee in
accordance with the University’s Nuclear Regulatory
Commission license. Activity was determined with a
Capintec CRC-25 Dose Calibrator calibrated to a factor of
465 for 89Zr (Capintec, Ramsey, NJ). All chemicals were
purchased from Sigma-Aldrich (St. Louis, MO), unless
otherwise specified, and all solutions were prepared using
ultrapure water with an 18 MΩ-cm resistivity produced by
a Millipore Integral 5 water purification system (Millipore,
Billerica, MA).

Fluorescence-activated cell sorting and analysis
For the evaluation of TEM-1 expression by FACS,
cell lines were plated in a 6-well format at 4x105 cells per
well in triplicate. At 24 hours, media was removed from
each well and collected into a labeled flow cytometry
tube. Each well was washed with 1X phosphate buffered
saline (PBS) (Life Technologies, Grand Island, NY) and
washings collected. Cells were treated with EFCD for 5-7
minutes (min) at 37°C. Cells were resuspended in PBS
and collected and centrifuged at 400g for 5 min and then
resuspended in a stock solution of 2% FBS and 2mM
EDTA in PBS (stock solution A). Primary labeling with
a 1:100 dilution of Ontuxizumab at 4°C for 30 min was
performed. After incubation, samples were centrifuged at
400g for 5 min, resuspended and washed with 1X PBS.
Secondary labeling was performed with 1:50 dilution of
FITC-labeled goat anti-human secondary antibody for
20-30 min at 4°C. After incubation, all samples were
centrifuged at 400g for 5 min and washed with PBS.
Finally, cell pellets were resuspended in 1%BSA + 2mM
EDTA + 1% sodium azide in 1X PBS. The antibody-free
unstained sample was provided for each cell line to allow
for proper gating and samples without primary antibody
labeling were also used to determine background. The
cell line (RD-ES) was used as a positive control in all
experiments. FACS analysis was performed with a Becton
Dickinson FACScan (BD Instruments, San Jose, CA) and
FlowJo X (FlowJo, LLC, Ashland, OR).

Cell lines and antibodies
Cell lines were purchased from ATCC, unless
otherwise specified. SYO-1 and FUJI were kindly
provided by Dr. Akira Kawai (National Cancer Centre
Hospital, Tokyo, Japan) and Dr. Kazuo Nagashima
(Hokkaido University School of Medicine, Sapporo,
Japan) and LUPI was a gift from Dr. John Pfeiffer
(Washington University in St. Louis). All complete
media was supplemented with 10% FBS and PenicillinStreptomycin 100x (10,000 U/mL) (Life Technologies,
Grand Island, NY). LUPI, RD-ES, SK-ES, FUJI and
RD lines were cultured in RPMI Medium 1640 (Life
Technologies, Grand Island, NY), SYO-1, ST-88 were
maintained in Dulbecco’s Modified Eagle Medium
(DMEM) (Life Technologies, Grand Island, NY), SKLMS-1, SK-UT-1, MG63, MNNG/HOS, HT-1080 were
cultured in Modified Eagle’s Medium (MEM) (Life
Technologies, Grand Island, NY), and U2-OS was
maintained in McCoy’s Medium (Life Technologies,
Grand Island, NY). All cell lines other than LUPI, SYO1 and FUJI are from ATCC and cultured less than six
months. The SYO-1 and FUJI cell lines were authenticated
by confirming the expression of the pathognomic SYTSSX fusion gene by RT-PCR and LUPO was authenticated
by confirming the expression of the pathognomic
EWS-Fli1 fusion gene by RT-PCR. All cell lines were
determined to be mycoplasma free using the LookOut
Mycoplasma PCR Detection kit. (Sigma-Aldrich, St.
Louis, MO).
For cell plating involved in fluorescence-activated
cell sorting (FACS) analysis, cells were passaged and
plated using 2.5mL of Enzyme-Free Cell Dissociation
Buffer (EFCD) (Life Technologies Cat# 13150-016).
Anti-TEM-1 antibody (MORAb-004; Ontuxizumab) was
provided by Morphotek, Inc. at a stock concentration of
5mg/mL and stored at 4°C. Anti-TEM-1 antibody (1D2.
www.impactjournals.com/oncotarget

Western blot analysis
Four cell lines (RD-ES, LUPI, SYO-1, FUJI) were
cultured, passaged, and dissociated utilizing media and
agents described above. Cell were collected, placed on
ice, and lysed with RIPA buffer over 40 min. Samples
were then centrifuged for 15 min at 4°C. Lysates were
transferred into a fresh tube with 4X LDS Loading Buffer
(Life Technologies). Samples were boiled at 100oC for
5 min, placed on ice, loaded on a NuPAGE 4-12% BisTris Gel 1.0 and run for 55 min at 170 Volts. Protein
was transferred onto filters (Novex iBlot 2 PVDF Mini
Stacks) via Novex iBlot2 Device (Life Technologies,
Grand Island, New York) and blocked with 5% milk in
1x 5% PBS-Tween for 2 hours at room temperature (RT).
The primary antibody to TEM-1 (Rat-Anti human 16D2.
13088

Oncotarget

Radiolabeling of anti-TEM-1 antibody

H12.E7.G9) at a concentration of 1µg/mL was added and
incubated overnight at 4°C. Filters were washed three
times in 1X PBS-Tween at RT for 15 min 5% PBS-Tween
was added to each blot along with HRP-Goat Anti-Rat IgG
at a concentration of 1:10,000 and incubated for 1 hour at
RT. Filters were washed 3 times in 1X PBS-Tween for 15
min at RT. SuperSignal WestFemto Maximum Sensitivity
Substrate Kit (ThermoScientific, Waltham, MA) was used
to prepare Femto Streptavidin 1:1 solution and applied
to filters. Images were captured via Omega Ultra-Lum
(Ultralum Inc.; Part #: 910-1024-12; Model: Omega 12iC;
Serial#: 6502) and analyzed for TEM-1 expression.

89
Zr labeling was performed according to previously
published methods [25, 26]. Briefly, Ontuxizumab
(5 mg/ml) was conjugated to isothiocyanatobenzyldesferrioxamine-NCS (Df-Bz-NCS) (Macrocyclics,
Dallas, TX) at 1:10 (Antibody) Ab to chelate ratio for 1
hour at 37°C in the presence of 0.1 M sodium carbonate
buffer (pH 9). The unreacted chelate was removed
utilizing Zeba desalting columns (40,000 MW cut off,
0.5 mL volume, ThermoFisher Scientific, Rockford,
IL). The Ab-Df-Bz-NCS conjugate was combined
with 89Zr oxalate at 1:1 or 1:5 mg/mCi and pH 7.1.
The mixture was incubated for one hour at 37°C. The
labeling efficiency was confirmed by radio-iTLC on glass
microfiber chromatography paper impregnated with silica
gel (Agilent Technologies, Lake Forest, CA) with 50
mM diethylene triamine pentaacetic acid (DTPA) eluent
solvent and a Bioscan AR- 2000 radio-TLC scanner
equipped with a 10% methane/argon gas supply. The
specific activity obtained was 1-5 µCi/µg with labeling
efficiency of 98-100%; therefore, the compounds were
used with no further purification.

Semi-quantitative immunofluorescence
All cell lines were plated at 5x104 cells/well onto
an 8-chamber slide. At two days after plating, the media
was removed from the wells and the slides were incubated
in a 4% paraformaldehyde for 10 min at RT. Slides were
washed with 1X PBS three times, then incubated in a
1X PBS and 50% goat serum for 30 min at 37°C. Slides
were incubated for one hour at 37°C in a 1:100 dilution
of primary antibody (Ontuxizumab) diluted in 1X PBS
and 50% goat serum. Slides were washed in 1X PBS 3
times and then incubated in a 1:100 dilution of FITClabeled goat anti-human secondary antibody (sc-2456,
Santa Cruz Biotech) for 1 hour at 37°C. Slides were
washed in 1X PBS 3 times, and mounted in Dapi/Antifade
solution (SlowFade Gold antifade reagent with DAPI).
Images were taken with a locked exposure time of 25
milliseconds using a 60x objective for FITC to allow for
semi-quantitative microscopy across all images.

In vitro cell binding
Cells were grown to ~50% confluence in 6-well
tissue culture plates and incubated with 1-2 µCi (0.5 µg)
of radiolabeled Ontuxizumab in 500 µL of complete media
for 35 min at 37°C. Unbound antibody was removed by
washing cells thrice with PBS. Cells were then solubilized
in PBS containing 0.1% SDS, the lysate was transferred
to microfuge tubes and cell associated activity detected
with a gamma-counter. Extra wells with untreated cells
corresponding to each cell line were assessed for cell
number and used as reference. The results were expressed
as counts per min per 5 x105 cells (CPM/5x105 cells).

Animal models
Nude athymic mice (Nu/J homozygous,
Cat#002019, The Jackson Lab) were xenografted with
1x106 RD-ES or LUPI cells that had been resuspended
in 1X PBS 30% Matrigel (Corning, Inc., Cat # CB40234). Mice were anesthetized with 1-2% isofluorane
and injected at the left shoulder for RD-ES xenografts and
injected at the right shoulder for LUPI xenografts. Mice
were observed until tumor size was 100mm3 and then
underwent small animal PET/CT imaging.
89

Internalization assay
Cells were plated in 24-well tissue culture plates
at 1x105 cells/well and incubated with 1-2 µCi (0.5 µg)
of radiolabeled antibody in 250 µl of complete media
per well for 0.5, 1, 2, 4, 6, and 24 hours in humidified
atmosphere supplemented with 5% CO2 at 37°C. Unbound
antibody was removed by washing cells three times with
PBS. Cells were then harvested by incubating in 250 µl
of 0.05% Trypsin-EDTA (Thermo Fisher) for 5 minutes
at 37°C. Cells were pelleted, the supernatant collected,
and the pellet re-suspended in 250 µl of 20 mM sodium
citrate/150 mM sodium chloride, pH 2.5 for 2 minutes at
22°C to remove the membrane associated antibody. Cells
were pelleted, the supernatant collected and combined with
the Trypsin supernatant to represent the membrane bound

Zr production and purification

Zr was produced via the 89Y(p,n)89Zr reaction using
the CS-15 cyclotron (Cyclotron Corporation, Berkeley,
CA) and separated via ion exchange chromatography
using an in-house automated system as previously
described [22-24], with a resulting specific-activity of 22134 mCi/μmole.
89
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antibody. The cell pellet was washed once with PBS. The
activity associated with the internalized (cell pellet) and
membrane bound (supernatants) was determined with a
gamma-counter.

Imaging Core.
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Small animal PET/CT imaging
Prior to imaging, mice were injected intravenously
(tail vein) with 100 µCi of 89Zr-Df-Bz-NCS-Ab. At three
and seven days post-injection mice were anaesthetized
with 1%-2% isoflurane and imaged with an Inveon small
animal PET/CT scanner (Siemens Medical Solutions).
Static images were collected for 20 min and reconstructed
with the Maximum A Posteriory (MAP) probability
algorithm [27] followed by co-registration with the Inveon
Research Workplace 4.0 (IRW) image display software
(Siemens Medical Solutions, Knoxville, TN). Regions
of interest (ROI) were selected from PET images using
CT anatomical guidelines and the activity determined
with IRW software. Standard uptake values (SUV) were
determined as nCi/cc x animal weight/ injected dose. To
block the binding of 89Zr labeled antibody, 40 mg/kg of
unlabeled antibody was injected intravenously (tail vein)
10 minutes prior to the labeled antibody.
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